Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period Launched BRUKINSA in the U.S. for adult patients with chronic lymphocytic
Recorded first quarter product revenue of $410.3 million, increasing 56.9% over $261.6 million from the prior-year period
Launched BRUKINSA® in the U.S. for adult patients with chronic. | May 4, 2023
/PRNewswire/ BridGene Biosciences, Inc., a biotechnology company leveraging a proprietary chemoproteomic platform to discover and develop small-molecule.
Recorded product revenue of $261.6 million for the first quarter, representing a 146% increase from $106.1 million in the prior year period BRUKINSA product revenue increased 372% globally